Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 17, 2012, by Cytosorbents Corporation, a critical care focused therapeutic medical device company. The report discloses a material definitive agreement entered into on February 10, 2012.
Key Financial Metrics and Transaction Details
The Company secured financing through the sale of convertible debentures. Key terms include:
- Principal Amount: $700,000
- Interest Rate: 8% annually
- Term: One year
- Conversion Price: $0.15 per share (automatic at maturity or at purchaser option)
- Shares upon Full Conversion: 4,666,667 shares of Common Stock
- Warrants Issued: 25% coverage, exercisable at $0.175 per share
- Use of Proceeds: Research and development and general and administrative purposes
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels prior to this transaction.
Material Changes and Unregistered Sales
The Company entered into a Debenture Purchase Agreement with accredited investors. The Notes and Warrants were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D. There are no anti-dilution provisions, no cash payment required for conversion, and no registration rights on the underlying common stock.
Guidance, Outlook, and Risks
Management indicated the financing is intended to strengthen the balance sheet. The filing references a press release dated February 13, 2012, titled "CytoSorbents Strengthens Balance Sheet through Convertible Note." No specific forward-looking guidance regarding revenue or earnings was provided in this text. The primary risk noted is the potential dilution of existing shareholders upon the conversion of the Notes and exercise of Warrants.
Investor Verification Checklist
- Verify the total number of outstanding shares prior to this issuance to calculate the exact dilution impact of the 4,666,667 potential new shares.
- Confirm the Company's current cash position and burn rate to assess if the $700,000 proceeds are sufficient for the stated R&D and administrative needs.
- Review the full text of the Convertible Debenture (Exhibit 10.1) for any covenants or default provisions not summarized here.
- Check subsequent filings to determine if the Notes were converted or repaid at maturity.